Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aveo’s cancer drug effective in preclinical study
AV-412 produced potent anti-tumor effects in several variants of EGFR kinase, including L858R and T790M double mutants, which are known to be resistant to erlotinib (Tarceva) and gefitinib
AV-412 produced potent anti-tumor effects in several variants of EGFR kinase, including L858R and T790M double mutants, which are known to be resistant to erlotinib (Tarceva) and gefitinib
The multi-national Phase IIa trial of ARC1779 is expected to enroll approximately 300 patients. The trial is a dose-ranging, randomized, double-blind study using ReoPro as a comparator. The
The Fast Track designation allows for frequent communications with the FDA and the possibility of submitting portions of the marketing application (a BLA) before the complete BLA is
The goal of this open-label, multi-center study is to determine the anti-tumor activity of IPI-504 in patients with hormone-refractory prostate cancer (HRPC), also referred to as castration-resistant prostate
The study is designed to evaluate efficacy of PH-10 in a total of 25 subjects with moderate to severe forms of the disease and will be conducted at
Under the terms of the agreement, Acambis will continue to perform development activities, up to and including the filing of a license application in the US. Acambis will
NV-52 is thought to work as a selective thromboxane synthase (TXS) inhibitor, which researchers believe may play a major therapeutic role in inflammatory bowel disease (IBD) due to
The Alphagenics human papillomaviruses (HPV) test in-licensed by Grant is a DNA-based diagnostic that uses standard molecular diagnostic equipment found in most commercial laboratories. Alphagenics Diaco’s HPV DNA
Ventana’s board believes that the due diligence process will allow Roche to recognize the significant additional value inherent in Ventana’s business. Ventana’s board of directors reiterated that Roche’s
Under the terms of the agreement, Nektar will receive a one-time payment of $135 million from Pfizer in satisfaction of all remaining obligations under existing agreements relating to